Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500351 | 0.89 | CKS1B (0.47) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL20500375 | 0.88 | CKS1B (0.46) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL23658236 | 0.87 | CKS1B (0.46) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL20500497 | 0.86 | CKS1B (0.45) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL21810232 | 0.86 | CKS1B (0.45) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL20500374 | 0.84 | CKS1B (0.43) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL20500373 | 0.81 | CKS1B (0.49) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL30078465 | 0.81 | CKS1B (0.49) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL21810255 | 0.80 | CKS1B (0.42) | CKS1BSKP1SKP2JAK3BTK | |
| SCHEMBL30078473 | 0.80 | TGM2 (0.46) | CNR1CNR2CTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608808-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | Basecamp Bio Inc. (KY) | 2025-09-03 | — | — | EP | disclosed |
| EP-4548974-A2 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3853218-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240408247-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4351653-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11834462-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230022513-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022261221-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220048924-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-02-17 | — | — | US | disclosed |
| US-11186590-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3853218-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283453-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-09-10 | — | — | US | disclosed |
| US-10696689-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| WO-2020061046-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20200087318-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022513-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
| US-20220048924-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
| US-20200087318-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
| US-20240408247-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | GRPR, SCTR, NPSR1 | CKS1B 3431/4885SKP1 4418/4885SKP2 3479/4885 |
| US-11834462-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
| US-20200283453-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
| US-11186590-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
| US-10696689-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.